PRN Stock Overview
Operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Profound Medical Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$11.07 |
| 52 Week High | CA$16.00 |
| 52 Week Low | CA$9.55 |
| Beta | 0.83 |
| 11 Month Change | 2.98% |
| 3 Month Change | -15.04% |
| 1 Year Change | -26.54% |
| 33 Year Change | -26.74% |
| 5 Year Change | 1.28% |
| Change since IPO | -26.20% |
Recent News & Updates
Recent updates
Does Profound Medical (TSE:PRN) Have A Healthy Balance Sheet?
May 03
Is Profound Medical (TSE:PRN) Using Debt In A Risky Way?
Sep 15Will Profound Medical (TSE:PRN) Spend Its Cash Wisely?
Sep 07Here's Why We're Not Too Worried About Profound Medical's (TSE:PRN) Cash Burn Situation
Jan 07We Think Profound Medical (TSE:PRN) Can Easily Afford To Drive Business Growth
Jul 02We Take A Look At Why Profound Medical Corp.'s (TSE:PRN) CEO Compensation Is Well Earned
May 13Shareholder Returns
| PRN | CA Medical Equipment | CA Market | |
|---|---|---|---|
| 7D | -3.1% | 7.2% | 0.2% |
| 1Y | -26.5% | 3.3% | 21.0% |
Return vs Industry: PRN underperformed the Canadian Medical Equipment industry which returned 1.9% over the past year.
Return vs Market: PRN underperformed the Canadian Market which returned 20.2% over the past year.
Price Volatility
| PRN volatility | |
|---|---|
| PRN Average Weekly Movement | 6.4% |
| Medical Equipment Industry Average Movement | 13.7% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.5% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: PRN has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: PRN's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 131 | Arun Menawat | www.profoundmedical.com |
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors.
Profound Medical Corp. Fundamentals Summary
| PRN fundamental statistics | |
|---|---|
| Market cap | CA$271.77m |
| Earnings (TTM) | -CA$44.23m |
| Revenue (TTM) | CA$12.66m |
21.6x
P/S Ratio-6.2x
P/E RatioIs PRN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRN income statement (TTM) | |
|---|---|
| Revenue | US$8.98m |
| Cost of Revenue | US$3.41m |
| Gross Profit | US$5.57m |
| Other Expenses | US$36.96m |
| Earnings | -US$31.39m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.27 |
| Gross Margin | 62.02% |
| Net Profit Margin | -349.41% |
| Debt/Equity Ratio | 18.0% |
How did PRN perform over the long term?
See historical performance and comparison